{
    "paper_id": "b951f9e7923eb094cf68715f2744c2e56cef83b1",
    "metadata": {
        "title": "COVID-19: impact of vaccination in myeloma patients",
        "authors": [
            {
                "first": "E",
                "middle": [],
                "last": "Hoornaert",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "addrLine": "10 avenue Hippocrate, 1200 Woluwe Saint Lambert",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "F"
                ],
                "last": "Dachy",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "A"
                ],
                "last": "Hansenne",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "S"
                ],
                "last": "Bailly",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "A"
                ],
                "last": "Van Maanen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques Universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "D"
                ],
                "last": "Gruson",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7 M-C",
                "middle": [],
                "last": "Vekemans",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cliniques universitaires Saint Luc",
                    "location": {
                        "postCode": "1200",
                        "settlement": "Brussels",
                        "country": "Belgium"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "The worldwide COVID-19 pandemic represents an unprecedented crisis that affects the entire medical community and appears to be a devastating infection in patients with hematological disorders, including myeloma (MM) [1] [2] [3] . Vaccination is therefore crucial in this population [4] . Seroconversion after COVID-19 has been shown to be lower in MM patients compared to the general population. The same is expected after vaccination, as different studies have already reported a lower antibody response after anti-SARS-CoV-2 vaccination in this group [5] [6] [7] [8] .",
            "cite_spans": [
                {
                    "start": 216,
                    "end": 219,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 220,
                    "end": 223,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 224,
                    "end": 227,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 282,
                    "end": 285,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 553,
                    "end": 556,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 557,
                    "end": 560,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 561,
                    "end": 564,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 565,
                    "end": 568,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "We investigated the impact of anti-SARS-CoV-2 vaccination in patients with MM or related disorders, excluding MGUS. Immunization was assessed after two shots of either a mRNA (Pfizer\u00ae/Moderna\u00ae) or a viral vector (Astra Zen-eca\u00ae) vaccine, using the Elecsys\u00ae immunoassay performed on cobas\u00ae8000 (Roche Diagnostics\u00ae) that measures anti-SARS-CoV-2 antibodies including IgG.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "From March 2020 to September 2021, we determined the serological status at day 30 (median 36, range 1-148), of the first 164 patients with plasma cell dyscrasias that completed vaccination. Among them, 114 were affected by MM, 26 by asymptomatic MM, 8 by MGRS, 16 by AL amyloidosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "The characteristics of our cohort were as followed: median age of 69 (range 35-89), median IgG level of 700 mg/dL (range 80-1840), median CD4/CD8 levels of 530/\u03bcL (range 58-1668), and 398/\u03bcL (range 33-4556), respectively (Fig. 1) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 221,
                    "end": 229,
                    "text": "(Fig. 1)",
                    "ref_id": null
                }
            ],
            "section": "Dear Editor,"
        },
        {
            "text": "One hundred fifty patients (92%) developed regular antibodies confirmed by the presence of the receptor-binding domain of the spike protein (RBD) antibodies, while 23 (14%) presented nucleocapsid protein (N) antibodies, suggesting a previous contact with the virus. Among these, 12 had a history of a positive RT-PCR nasopharyngeal swab and 11 were fortuitously found to be positive in the absence of any clinical manifestation (Fig. 1) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 428,
                    "end": 436,
                    "text": "(Fig. 1)",
                    "ref_id": null
                }
            ],
            "section": "Dear Editor,"
        },
        {
            "text": "Thirteen patients failed to develop any immunization; all had received immunosuppressive therapies (renal transplantation in 1, long-term corticosteroids in 2, cyclophosphamide in 4, anti-CD20 monoclonal antibodies in 4, both in 2) or multiple lines of therapies in 1. We failed to identify any link with immunoparesis or CD4/CD8 levels. As well, there was no correlation between RBD antibody and CD4 levels. All patients tested after the third dose develop immunization except those exposed to anti-CD20 therapies in the previous 12 months. Only one patient underwent an interferongamma-release assay testing that was negative.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "Nowadays, with an 8-month median follow up after vaccination, if only 5 patients experienced a mild form of COVID-19 during the Delta-variant wave, more patients (n = 12) are tested positive with the emergence of the omicron variant, but there were no significant clinical manifestations, hospitalizations, or deaths.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "In conclusion, SARS-CoV-2 vaccination provided an adequate coverage in our MM population during the delta wave since only five patients developed a mild infection after vaccination. Seroconversion was however clearly affected by the anti-MM treatment. With the appearance of the omicron variant, we observed an upsurge of cases, even of benign evolution, which questions this protection. Whether nonresponding patients will eventually develop T cell protection against COVID-19 remains also to be answered, as well as the positivity cutoff that measures neutralizing antibodies, the optimal vaccination schedule, particularly in the context of immunodeficiency, and diverse anti-MM therapies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Impact of COVID-19 on myeloma patients",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Dufour",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ann Hematol",
            "volume": "99",
            "issn": "",
            "pages": "1947--1949",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Cook",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Haematol",
            "volume": "190",
            "issn": "",
            "pages": "83--86",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hultcranz",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Blood Cancer Discovery",
            "volume": "1",
            "issn": "",
            "pages": "234--2343",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ludwig",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Leukemia",
            "volume": "35",
            "issn": "",
            "pages": "31--44",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Response to first vaccination against SARS-CoV-2 patients with multiple myeloma",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bird",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Lancet Haematol",
            "volume": "6",
            "issn": "",
            "pages": "389--392",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pimpinelli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Haematol Oncol",
            "volume": "14",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1186/s13045-021-01090-6"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Oekelen",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Cancer Cell",
            "volume": "39",
            "issn": "",
            "pages": "1028--1030",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Terpos",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Blood Cancer J",
            "volume": "11",
            "issn": "8",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": []
}